FAP and neoplasm: Huang et al. recently demonstrated that a universal anti-fluorescein CAR-T cell platform, when combined with two bispecific adapters, one targeting tumor cells via folate/FRα and the other targeting CAFs via a FAP ligand, can simultaneously eliminate cancer cells and CAFs [130].